Similar results were seen with another oral pan-HDAC inhibitor, panobinostat, which resulted in an ORR of 28% (CR in 18%) when given alone or in combination with rituximab in 40 patients with relapsed/refractory DLBCL [79]. This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.